Gibson Dunn (Washington)

Michael J. Perry

Gibson Dunn (Washington)

Michael Perry is a Partner in the Antitrust and Competition Practice at Gibson Dunn. He focuses on advising clients in merger and non-merger antitrust investigations before the Federal Trade Commission and the U.S. Department of Justice, and in complex private and government antitrust litigation. Mr. Perry has particular experience in the healthcare, life sciences, and technology sectors, including issues involving the intersection of antitrust and intellectual property law. Mr. Perry recently joined the firm after serving as Counsel to the Director of the Federal Trade Commission’s Bureau of Competition from 2015 to 2016. In that front-office role, he was directly involved in many of the agency’s most important antitrust enforcement actions, including both merger and non-merger matters. He played an integral role in the FTC’s challenge to the proposed Sysco/U.S. Foods merger and other high-profile cases such as FTC v. Actavis, FTC v. Cephalon, FTC v. Advocate Health, and FTC v. St. Luke’s Health System.


Auteurs associés

King’s College (London)
Gibson Dunn (Brussels)
Gibson Dunn (San Francisco)
Gibson Dunn (New York)
Gibson Dunn (Dubai)


Michael Perry (Baker Botts)
Michael J. Perry 20 septembre 2018 Brussels


67 Bulletin

Nathan Chubb, Catriona Hatton, Michael J. Perry, Stephen Weissman The US Government Accountability Office publishes the results of its study into the prescription drug industry


Prior to the year-end holiday season, the United States Government Accountability Office (“GAO”) released the results of its long-awaited study into the prescription drug industry’s “Profits, Research and Development Spending, and Merger and Acquisition Deals.” The report responds to Congressional (...)

Envoyer un message